Curcumin as a novel epigenetic treatment approach for gfi1-associated mds/aml

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are diseases caused by an ineffective myelopoiesis. AML is an aggressive blood cancer with poor prognosis for patients despite treatment with intensive chemotherapy, hence alternative therapies are needed. MDS and AML patients with low expression of the transcriptional repressor GFI1 (Growth factor independence 1) or expression of the GFI1 variant GFI1-36N (asparagine instead of serine at amino acid position 36) in their blast cells have an even poorer prognosis.

Source: Experimental Hematology - July 31, 2019 Category: Hematology Authors: Judith Sch ütte, Aniththa Thivakaran, Dennis Heinrichs, Yahya Al-Matary, Lothar Vaßen, Pradeep Patnana, Daria Frank, Marina Suslo, Ulrich Dührsen, Cyrus Khandanpour Tags: 3122 Source Type: research